Literature DB >> 20022516

Surgical treatment of synchronous multiple lung cancer located in a different lobe or lung: high survival in node-negative subgroup.

Luca Voltolini1, Cristian Rapicetta, Luca Luzzi, Claudia Ghiribelli, Piero Paladini, Felice Granato, Mariasole Gallazzi, Giuseppe Gotti.   

Abstract

BACKGROUND: The International Association for Study of Lung Cancer Staging Committee proposes for the next revision of TNM (tumour, nodes, metastases) classification that additional nodules in a different lobe of the ipsilateral lung moves from an M1 designation to T4, while additional nodule(s) in the contralateral lung should be classified as M1a, because of poorer survival. We analysed the survival after surgery of patients presenting with synchronous lung cancers located in a different lobe or lung.
METHODS: A database of 1551 patients operated on for non-small-cell lung cancer (NSCLC) between 1990 and 2007 was evaluated for unilateral (other lobe) (n=15) and bilateral (n=28) synchronous multiple lung cancers. The relationships among the location of tumours, histology, date of surgery (before and after 2000), lymph node metastasis, type of surgery, adjuvant therapy and survival were analysed.
RESULTS: The 5-year survival for all synchronous multiple lung cancers (n=43) was 34%, with a median survival of 32 months. Postoperative mortality was 7%. On univariate analysis, only lymph node metastasis and surgery before the year 2000 affected the overall survival adversely, and both prognostic factors maintained a statistical significance on multivariate analysis. The 5-year survivals were 57% and 0% for patients without (n=25) and with (n=18) lymph node metastasis, respectively (p=0.004), and were 43% and 18% for patients operated upon after (n=27) and before (n=16) the year 2000, respectively (p=0.01), perhaps reflecting a better selection process related to the extensive use of positron emission tomography (PET) scanning. The 5-year survival was not different between bilateral (43%) and unilateral (27%) synchronous lung cancers (p=n.s.).
CONCLUSIONS: Our data support complete surgical resection of synchronous multiple lung cancers in patients with node-negative NSCLC. Even patients with bilateral lung cancer should not be treated as metastatic disease. Provided there is no evidence of node and distant metastasis, after an extensive preoperative work-up, including PET scanning and mediastinoscopy, bilateral surgical resection should be performed in fit patients. Copyright 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 20022516     DOI: 10.1016/j.ejcts.2009.11.025

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  31 in total

1.  Impact of a Contralateral Tumor Nodule on Survival in Non-Small-Cell Lung Cancer.

Authors:  Zachary S Morris; Donald M Cannon; Brett A Morris; Søren M Bentzen; Kevin R Kozak
Journal:  J Thorac Oncol       Date:  2015-11       Impact factor: 15.609

2.  The equivalent efficacy of multiple operations for multiple primary lung cancer and a single operation for single primary lung cancer.

Authors:  Liang Dai; He-Li Yang; Wan-Pu Yan; Zhen Liang; Hong-Chao Xiong; Xiao-Zheng Kang; Yong-Bo Yang; Hao Fu; Meng-Ying Fan; Ke-Neng Chen
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

3.  Significance of nonmucinous lepidic component with mild nuclear atypia in the discrimination of multiple primary lung cancers from intrapulmonary metastases.

Authors:  Wei Sun; Yu Liu; Xiang-Yang Liu; Dong-Mei Lin; Ning Lv
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

4.  Management of Multifocal Lung Cancer: Results of a Survey.

Authors:  Konstantinos Leventakos; Tobias Peikert; David E Midthun; Julian R Molina; Shanda Blackmon; Francis C Nichols; Yolanda I Garces; Christopher L Hallemeier; Stephen J Murphy; George Vasmatzis; Sarah L Kratz; William P Holland; Charles F Thomas; John J Mullon; K Robert Shen; Stephen D Cassivi; Randolph S Marks; Marie Christine Aubry; Alex A Adjei; Ping Yang; Mark S Allen; Eric S Edell; Dennis Wigle; Aaron S Mansfield
Journal:  J Thorac Oncol       Date:  2017-06-03       Impact factor: 15.609

Review 5.  Risk factors and management of oligometastatic non-small cell lung cancer.

Authors:  Akshar N Patel; Charles B Simone; Salma K Jabbour
Journal:  Ther Adv Respir Dis       Date:  2016-04-08       Impact factor: 4.031

6.  Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.

Authors:  Helena A Yu; Camelia S Sima; James Huang; Stephen B Solomon; Andreas Rimner; Paul Paik; M Catherine Pietanza; Christopher G Azzoli; Naiyer A Rizvi; Lee M Krug; Vincent A Miller; Mark G Kris; Gregory J Riely
Journal:  J Thorac Oncol       Date:  2013-03       Impact factor: 15.609

7.  Surgical treatment of synchronous multiple primary lung cancers: a retrospective analysis of 122 patients.

Authors:  Ming Liu; Wenxin He; Jie Yang; Gening Jiang
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

8.  Screen-detected multiple primary lung cancers in the ITALUNG trial.

Authors:  Mario Mascalchi; Camilla E Comin; Elena Bertelli; Lapo Sali; Cristina Maddau; Stefania Zuccherelli; Giulia Picozzi; Laura Carrozzi; Michela Grazzini; Gabriella Fontanini; Luca Voltolini; Alessandra Vella; Francesca Castiglione; Francesca Carozzi; Eugenio Paci; Maurizio Zompatori; Andrea Lopes Pegna; Fabio Falaschi
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

9.  Long-term results after surgical treatment of the dominant lung adenocarcinoma associated with ground-glass opacities.

Authors:  Stefano Bongiolatti; Roberto Corzani; Sara Borgianni; Fabiola Meniconi; Fabrizio Cipollini; Alessandro Gonfiotti; Domenico Viggiano; Piero Paladini; Luca Voltolini
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

10.  Prior Treatment for Non-small Cell Lung Cancer Is Associated With Improved Survival in Patients who Undergo Definitive Stereotactic Body Radiation Therapy for a Subsequent Lung Malignancy: A Retrospective Multivariate and Matched Pair Analysis.

Authors:  Mark K Farrugia; Sung Jun Ma; Mark W Hennon; Chukwumere E Nwogu; Elisabeth U Dexter; Anthony L Picone; Todd L Demmy; Jorge A Gomez-Suescun; Simon Fung-Kee-Fung; Sai S Yendamuri; Anurag K Singh
Journal:  Am J Clin Oncol       Date:  2021-01-01       Impact factor: 2.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.